BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29025906)

  • 21. A large-scale computational study of inhibitor risk in non-severe haemophilia A.
    Shepherd AJ; Skelton S; Sansom CE; Gomez K; Moss DS; Hart DP
    Br J Haematol; 2015 Feb; 168(3):413-20. PubMed ID: 25244644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated dermal fibroblasts.
    Maurer DH; Hanke JH; Mickelson E; Rich RR; Pollack MS
    J Immunol; 1987 Aug; 139(3):715-23. PubMed ID: 3110281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A.
    Diego VP; Luu BW; Hofmann M; Dinh LV; Almeida M; Powell JS; Rajalingam R; Peralta JM; Kumar S; Curran JE; Sauna ZE; Kellerman R; Park Y; Key NS; Escobar MA; Huynh H; Verhagen AM; Williams-Blangero S; Lehmann PV; Maraskovsky E; Blangero J; Howard TE
    J Thromb Haemost; 2020 Jan; 18(1):201-216. PubMed ID: 31556206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA.
    Jucaud V
    J Immunol Res; 2017; 2017():2748614. PubMed ID: 28331856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
    Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
    J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Revisiting the structural basis and energetic landscape of susceptibility difference between HLA isotypes to allergic rhinitis.
    Mao XL; Zhu F; Pan ZH; Wu GM; Zhu HY
    Comput Biol Chem; 2016 Oct; 64():210-216. PubMed ID: 27433817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Functional difference between HLA-DR and HLA-DQ molecules in mixed lymphocyte reaction].
    Fujisawa K
    Fukuoka Igaku Zasshi; 1989 Jan; 80(1):49-59. PubMed ID: 2524437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cell alloresponses against HLA-DQ and -DR products involve multiple epitopes on the CD4 molecule. Distinct mechanisms contribute to the inhibition of HLA class II-dependent and -independent T cell responses by antibodies to CD4.
    Merkenschlager M; Altmann DM; Ikeda H
    J Immunol; 1990 Nov; 145(10):3181-7. PubMed ID: 1699999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Both HLA-DR and HLA-DQ determinants contribute to HLA-Dw typing.
    Sterkers G; Zeliszewski D; Freidel AC; Gebuhrer L; Betuel H; Levy JP
    Hum Immunol; 1987 Nov; 20(3):233-47. PubMed ID: 2449409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In cutaneous T-cell lymphoma, class II MHC molecules on CD1+ antigen-presenting cells are upregulated in involved compared with uninvolved epidermis.
    Hansen ER; Bang B; Larsen JK; Vejlsgaard GL; Baadsgaard O
    Br J Dermatol; 1994 Dec; 131(6):780-8. PubMed ID: 7531998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity.
    Mommen GP; Marino F; Meiring HD; Poelen MC; van Gaans-van den Brink JA; Mohammed S; Heck AJ; van Els CA
    Mol Cell Proteomics; 2016 Apr; 15(4):1412-23. PubMed ID: 26764012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
    Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
    Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA antigens in hemophiliacs A with or without factor VIII antibodies in a Venezuelan Mestizo population.
    Simonney N; De Bosch N; Argueyo A; Garcia E; Layrisse Z
    Tissue Antigens; 1985 Apr; 25(4):216-9. PubMed ID: 3925592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Removal of Mannose-Ending Glycan at Asn
    Delignat S; Rayes J; Dasgupta S; Gangadharan B; Denis CV; Christophe OD; Bayry J; Kaveri SV; Lacroix-Desmazes S
    Front Immunol; 2020; 11():393. PubMed ID: 32273875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes.
    Tsujisaki M; Igarashi M; Sakaguchi K; Eisinger M; Herlyn M; Ferrone S
    J Immunol; 1987 Feb; 138(4):1310-6. PubMed ID: 3100635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breadth of the CD4+ T cell response to Anaplasma marginale VirB9-1, VirB9-2 and VirB10 and MHC class II DR and DQ restriction elements.
    Morse K; Norimine J; Hope JC; Brown WC
    Immunogenetics; 2012 Jul; 64(7):507-23. PubMed ID: 22361828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.
    van Lith M; McEwen-Smith RM; Benham AM
    J Biol Chem; 2010 Dec; 285(52):40800-8. PubMed ID: 20959457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HLA-DQB1 alleles may influence the surface expression of DQ molecules in lymphomononuclear cells of type 1 diabetes mellitus patients.
    Fernandes AP; Foss MC; Donadi EA
    Scand J Immunol; 2004 Mar; 59(3):305-9. PubMed ID: 15030582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro.
    Rombach-Riegraf V; Karle AC; Wolf B; Sordé L; Koepke S; Gottlieb S; Krieg J; Djidja MC; Baban A; Spindeldreher S; Koulov AV; Kiessling A
    PLoS One; 2014; 9(1):e86322. PubMed ID: 24466023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.